Arcus biosciences stock.

Nov 23, 2023 · Arcus Biosciences Stock Performance. NYSE RCUS opened at $13.87 on Thursday. Arcus Biosciences has a one year low of $12.95 and a one year high of $36.13. The firm’s fifty day moving average is $16.47 and its two-hundred day moving average is $18.74. The firm has a market cap of $1.04 billion, a PE ratio of -3.47 and a beta of 0.76. SVP, Technology & Quantitative Biology. Dr. Young has held scientific, technical, and leadership roles across Europe and the U.S. since 1993, most recently as VP of Technology at Flexus Biosciences and FLX Bio. He was the first scientist at Flexus and built the company’s biology and IT/informatics functions from the ground up ….16 кра 2020 г. ... Shares of cancer drug developer Arcus Biosciences skyrocketed as much as 99% in Thursday trading after Bloomberg reported biotech firm Gilead ...Arcus Biosciences, Inc. Appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...While ratings are subjective and will change, the latest Arcus Biosciences ( RCUS) rating was a maintained with a price target of $46.00 to $36.00. The current price Arcus Biosciences ( RCUS) is ...

SVP, Technology & Quantitative Biology. Dr. Young has held scientific, technical, and leadership roles across Europe and the U.S. since 1993, most recently as VP of Technology at Flexus Biosciences and FLX Bio. He was the first scientist at Flexus and built the company’s biology and IT/informatics functions from the ground up …. HAYWARD, Calif., December 24, 2022--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Nov 27, 2023 · Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug. Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules ...

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting ... Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. Shares of Arcus Biosciences stock opened at $13.87 on Thursday. The company has a market capitalization of $1.04 billion, a P/E ratio of -3.47 and a beta of 0.76. Arcus Biosciences has a 1 year low of $12.95 and a 1 year high of $36.13. The company’s fifty day moving average is $16.47 and its two-hundred day moving average is $18.74.Apr 16, 2020 · Arcus Biosciences, Inc. (RCUS-5.44%), a clinical-stage oncology company, is up big this morning. Specifically, the drugmaker's shares are up by an astounding 84% as of 10:16 a.m. EDT Thursday morning. Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with Gilead, Roche/Genentech, and AstraZeneca, and ...

Competitors. RCUS | Complete Arcus Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Get the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. See the current price, performance outlook, earnings date, dividend yield, fair value and more.

Nov 7, 2023 · Analyst Mara Goldstein of Mizuho Securities maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $51.00. Mara Goldstein’s Buy recommendation for Arcus ... Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug. Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that ...ARCUS BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $15.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety …Camaraderie, teamwork, integrity. The complexity and cross-functional nature of what we do makes strong teamwork essential to our success. We take pride in hard work and approach our mission with a great sense of urgency. We embrace innovative mindsets and the change this brings. And finally, we aspire to operate with simplicity and common ... Complete Arcus Biosciences Inc. stock information by Barron's. View real-time RCUS stock price and news, along with industry-best analysis.

Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today. 502%. Motley Fool Returns. Market-beating stocks from our award-winning analyst team. Stock Advisor Returns. 502% .Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to loss of $1.11 per share a year ago.Currently, Arcus Biosciences has an average volume of 1.19M. Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock.Get the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. See the current price, performance outlook, earnings date, dividend yield, fair value and more. Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently down 4.32% so far this month. During the month of August, Arcus Biosciences Inc’s stock price has reached a high of $19.72 and a low of $17.25. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $15.70. Year to …Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug. Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that ...Arcus Biosciences Stock Performance. NYSE RCUS opened at $13.87 on Thursday. Arcus Biosciences has a one year low of $12.95 and a one year high of $36.13. The firm’s fifty day moving average is $16.47 and its two-hundred day moving average is $18.74. The firm has a market cap of $1.04 billion, a PE ratio of -3.47 and a beta of 0.76.

On average, Wall Street analysts predict that Arcus Biosciences's share price could reach $44.38 by Nov 13, 2024. The average Arcus Biosciences stock price ...Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without …

Arcus Biosciences, Inc.'s latest quarterly earnings per share is $-0.94 with a past EPS surprise of $0.18. The latest EPS estimate is $-1.02. Read more about ...RCUS POWR Grades. Value is the dimension where RCUS ranks best; there it ranks ahead of 69.33% of US stocks. RCUS's strongest trending metric is Quality; ...ARCUS BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $15.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety …Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, ... 2023, and restricted stock units to acquire a total of 6,300 shares of the Company’s common stock.Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting ...Which technical analysis tools can be used to analyze Arcus Biosciences, Inc.? Check out various oscillators, moving averages and other technical indicators ...View the latest Arcus Biosciences Inc. (RCUS) stock price, news, historical charts, analyst ratings and financial information from WSJ.Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to earnings of $3.71 per share a year ago.During the last session, Arcus Biosciences Inc (NYSE:RCUS)’s traded shares were 0.88 million, with the beta value of the company hitting 0.75. At the end of the trading day, the stock’s price was $16.01, reflecting an intraday loss of -2.67% or -$0.44. The 52-week high for the RCUS share is $36.Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug. Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in …

Sell candidate since Nov 09, 2023 Gain 2.33% PDF. No changes to the price of Arcus Biosciences Inc. stock on the last trading day (Monday, 27th Nov 2023). During the last trading day the stock fluctuated 4.63% from a day low at $13.50 to a day high of $14.12. The price has risen in 5 of the last 10 days and is up by 3.84% over the past 2 weeks.

View the latest Arcus Biosciences Inc. (RCUS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Track Arcus Biosciences Inc (RCUS) Stock Price, Quote, latest community messages, chart, news and other stock related information.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to ...Concurrent with the May 2020 collaboration agreement, Gilead and Arcus entered into a stock purchase agreement under which Gilead made a $200 million equity investment in Arcus. That stock ...Arcus Biosciences Inc recently saw a daily gain of 27.7% and a 3-month gain of 29.03%.However, with a Loss Per Share of 3.96, is the stock truly undervalued? This article provides a comprehensive ...Arcus Biosciences is a biopharmaceutical company that focuses on creating innovative cancer immunotherapies. The stock price, earnings, news, and research reports for RCUS are available on Zacks. See the latest updates on the company's product portfolio, performance, and outlook.Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting ...Arcus Biosciences, Inc. Stock price Equities RCUS US03969F1093 Biotechnology & Medical Research Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds and ETFs Financials (USD) More Fundamentals * Assessed data Chart Arcus Biosciences, Inc. Duration Period Style Dynamic ChartIf you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Arcus Biosciences is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. If you are thinking of buying or selling Arcus Biosciences stock, you ...

Arcus Biosciences, Inc. Appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...ARCUS BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $15.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety …I last covered Arcus Biosciences (NYSE:RCUS) for Seeking Alpha back in March 2020, giving the company' stock a "BUY" rating - more than 3 years later, Arcus stock has reached a value of $20 at the ...With a median price-to-sales (or "P/S") ratio of close to 11.6x in the Biotechs industry in the United States, you could be forgiven for feeling indifferent about Arcus Biosciences, Inc.'s () P/S ...Instagram:https://instagram. nasdaq dmtkhumana dental insurance for retired militaryfinancial blogsvgt index fund Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. nyse tlsashibu inu news Analyst Mara Goldstein of Mizuho Securities maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $51.00. Mara Goldstein’s Buy recommendation for Arcus ... holidays of stock exchange Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently down 6.1% so far this month. During the month of February, Arcus Biosciences Inc’s stock price has reached a high of $22.75 and a low of $18.96. Over the last year, Arcus Biosciences Inc has hit prices as high as $39.75 and as low as $16.74. Year to …Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently down 6.96% so far this month. During the month of April, Arcus Biosciences Inc’s stock price has reached a high of $18.51 and a low of $16.94. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $15.70. Year to date ...